Klingman & Associates LLC Buys 2,753 Shares of Novo Nordisk A/S $NVO

Klingman & Associates LLC raised its stake in Novo Nordisk A/S (NYSE:NVO) by 83.4% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 6,055 shares of the company’s stock after purchasing an additional 2,753 shares during the period. Klingman & Associates LLC’s holdings in Novo Nordisk A/S were worth $418,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Copeland Capital Management LLC lifted its position in Novo Nordisk A/S by 184.8% in the 1st quarter. Copeland Capital Management LLC now owns 393 shares of the company’s stock valued at $27,000 after acquiring an additional 255 shares in the last quarter. North Capital Inc. bought a new position in Novo Nordisk A/S in the 1st quarter valued at about $27,000. Stone House Investment Management LLC bought a new position in Novo Nordisk A/S in the 1st quarter valued at about $30,000. Disciplina Capital Management LLC lifted its position in Novo Nordisk A/S by 162.3% in the 1st quarter. Disciplina Capital Management LLC now owns 480 shares of the company’s stock valued at $33,000 after acquiring an additional 297 shares in the last quarter. Finally, Dagco Inc. bought a new position in Novo Nordisk A/S in the 1st quarter valued at about $35,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Down 1.7%

NVO opened at $54.77 on Wednesday. The company has a quick ratio of 0.56, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. The stock has a market cap of $244.55 billion, a price-to-earnings ratio of 15.05, a PEG ratio of 2.53 and a beta of 0.68. Novo Nordisk A/S has a twelve month low of $45.05 and a twelve month high of $116.65. The company’s 50-day moving average price is $56.46 and its two-hundred day moving average price is $62.58.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Wednesday, August 6th. The company reported $0.97 earnings per share for the quarter, beating analysts’ consensus estimates of $0.93 by $0.04. The firm had revenue of $11.69 billion for the quarter, compared to analysts’ expectations of $77.51 billion. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. As a group, equities analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The firm also recently declared a semi-annual dividend, which was paid on Tuesday, August 26th. Stockholders of record on Monday, August 18th were given a $0.4119 dividend. The ex-dividend date of this dividend was Monday, August 18th. This represents a dividend yield of 240.0%. Novo Nordisk A/S’s payout ratio is 22.53%.

Analyst Ratings Changes

Several equities analysts recently weighed in on NVO shares. Rothschild Redb raised shares of Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, September 16th. Wall Street Zen cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Saturday, August 2nd. Barclays restated an “equal weight” rating on shares of Novo Nordisk A/S in a report on Wednesday, July 30th. BNP Paribas upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “neutral” rating in a report on Wednesday, August 13th. Finally, BNP Paribas Exane upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “neutral” rating and set a $54.00 price target on the stock in a report on Wednesday, August 13th. Two analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $76.00.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.